Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | FGF2 | P09038 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | PPP5C | P53041 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24212765 | 1.00 | TK1 (0.34) | TK1PPM1BPTPN1PPP1CCFGF2 | |
| SCHEMBL15357448 | 1.00 | TK1 (0.34) | TK1PPM1BPTPN1PPP1CCFGF2 | |
| SCHEMBL22828158 | 1.00 | TK1 (0.34) | TK1PPM1BPTPN1PPP1CCFGF2 | |
| SCHEMBL20131876 | 0.82 | RAB9A (0.31) | FGF2 | |
| SCHEMBL22828540 | 0.80 | LGALS8 (0.36) | TK1PPM1BPTPN1PPP1CC | |
| SCHEMBL24212703 | 0.80 | LGALS8 (0.36) | TK1PPM1BPTPN1PPP1CC | |
| SCHEMBL17267039 | 0.80 | LGALS8 (0.36) | TK1PPM1BPTPN1PPP1CC | |
| SCHEMBL21767050 | 0.77 | TK1 (0.40) | TK1 | |
| SCHEMBL21134683 | 0.77 | — | — | |
| SCHEMBL21765949 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180126000-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180126000-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | TK1 2715/4885PPM1B 4322/4885PTPN1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.